Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older
Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older |
| [28-September-2026] |
KIRKLAND, QC, Sept. 28, 2026 /CNW/ -- Organon Canada, a global healthcare company, today announces the approval and availability of NDUVRA® (tapinarof cream), 1%, for the topical treatment of moderate to severe atopic dermatitis in adult and pediatric patients 2 years of age and older.
"Winter is coming, and with it, the dry, cold, and windy climate that frequently results in flares for patients with atopic dermatitis, an inflammatory skin condition that can have a significant impact on sleep, mental health, and quality of life. The approval and now availability of tapinarof cream are welcome additions to the range of treatment options currently available," said Dr. Vimal H. Prajapati, Clinical Associate Professor at the University of Calgary, Dermatologist (Co-founder and Co-director) of the Skin Health & Wellness Centre, Dermatology Research Institute, Dermphi Centre, and Dermphi Shop, and Councillor for the International Eczema Council. NDUVRA® (tapinarof cream) is a topical aryl hydrocarbon receptor agonist formulated with tapinarof.i,ii,iii,iv Its approval for atopic dermatitis builds on a distinctly Canadian research story as tapinarof was discovered in Canada, and its clinical development has included participant enrolment at study sites across the country. "Patients I see with atopic dermatitis are often looking for relief from symptoms and a non steroid treatment option that can be started promptly. Tapinarof cream provides family physicians with an additional topical treatment option that can be prescribed without requiring specialist referral, helping eligible patients access care sooner," said Dr. Simraaj Powar, Family Physician. Atopic Dermatitis, also known as eczema, is one of the most common chronic inflammatory skin diseases globally, affecting up to 20% of children and 3% of adults, with a higher prevalence among womenv,vi,vii In Canada, AD affects approximately 15% of children and 4% of adults.viii Women with these skin conditions carry a disproportionate psychosocial burden, often reporting greater levels of depression, anxiety, fatigue, loneliness and stigma.ix,x "Atopic dermatitis is a chronic condition that can have a profound impact on patients and their families, from children living with the condition from an early age to women who may experience disease flares during the menstrual cycle, pregnancy, and menopausexi," said Dominic Bégin, President and Managing Director, Organon Canada. "The availability of tapinarof cream for adults and children reflects our commitment to expanding our dermatology portfolio and providing more treatment options for people living with this disease. For us, what matters most is helping support patients in managing their condition." This marks the second approved indication for tapinarof cream in Canada, following its initial approval in 2025 for the treatment of plaque psoriasis in adults. For more information about NDUVRA® (tapinarof cream), including important safety information, visit https://www.organon.com/canada-en/wp-content/uploads/sites/5/2025/04/NDUVRA_PM_E.pdf About Organon For more information, visit https://www.organon.com/canada-en/ and connect with us on LinkedIn.
SOURCE Organon Canada Inc. | |||||||||||||||
Company Codes: NYSE:OGN |
